| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Research Unit, Smith Kline &French Laboratories Philadelphia, PA
Growth hormone-releasing peptide (GHRP, SK&F 110679) is a hexapeptide (His-DTrp-Ala-Trp-DPhe-LysNH2) that selectively stimulates the release of growth hormone (GH) but not other pituitary hormones in vitro and in vivo in a variety of animal species. GHRP was administered to 17 normal men at doses of from 0.05 to 2.5 µg/ kg as a 30 min intravenous infusion. Eight of the men were infused with saline as a control. Serum GH increased consistently at doses of 0.25 µg/kg and above during the infusion of the peptide, peaked at 45 min and then decreased to baseline values by 210 min. The mean peak serum GH concentrations (± SE) in response to GHRP infusion were 17.8±6.1 µg/L at a dose of 0.25 µg/kg (n=4, p=. 03 vs saline), 38.3±9.2 µg/L at 0.5 µg/kg (n=4, P=.O4 vs saline) and 63.0±5.4 µg/L at 1.0 µg/kg (n=4, p=.002 vs saline). Serum LH, FSH, TSH and ACTH were unaffected by GHRP administration. GHRP was safe and well-tolerated in all men. GHRP infusion resulted in a dramatic, selective and dose-dependent increase in serum GH concentrations.
Received January 27, 1989.
Revised March 17, 1989.
This article has been cited by other articles:
 |
|
 |
|
  M. G. Murphy, S. Weiss, M. McClung, T. Schnitzer, K. Cerchio, J. Connor, D. Krupa, and B. J. Gertz Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1116 - 1125. [Abstract] [Full Text]
|
|
|
|
|
|
A.-C. A. R. Pinto, M. R. D. Silva, M. R. Martins, E. Brunner, and A.-M. J. Lengyel Effects of Short-Term Glucocorticoid Deprivation on Growth Hormone (GH) Response to GH-Releasing Peptide-6: Studies in Normal Men and in Patients with Adrenal Insufficiency J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1540 - 1544. [Abstract] [Full Text]
|
|
|
|
|
|
M. Korbonits, G. Kaltsas, L. A. Perry, P. Putignano, A. B. Grossman, G. M. Besser, and P. J. Trainer The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2489 - 2495. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-M. Frieboes, H. Murck, G. K. Stalla, I. A. Antonijevic, and A. Steiger Enhanced Slow Wave Sleep in Patients with Prolactinoma J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2706 - 2710. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. F. Carmignac, P. A. Bennett, and I. C. A. F. Robinson Effects of Growth Hormone Secretagogues on Prolactin Release in Anesthetized Dwarf (dw/dw) Rats Endocrinology, August 1, 1998; 139(8): 3590 - 3596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Murphy, L. M. Plunkett, B. J. Gertz, W. He, J. Wittreich, W. M. Polvino, and D. R. Clemmons MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 320 - 325. [Abstract] [Full Text]
|
|
|
|
|
|
I. M. Chapman, O. H. Pescovitz, G. Murphy, T. Treep, K. A. Cerchio, D. Krupa, B. Gertz, W. J. Polvino, E. H. Skiles, S. S. Pezzoli, et al. Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3455 - 3463. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
